EMA CHMP[removed]EMEA H C 202 - Erectile dysfunction - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2013-07-21 05:37:53 Lactams Pfizer Human sexuality Piperazines Pyrazolopyrimidines Sildenafil CGMP-specific phosphodiesterase type 5 Erectile dysfunction Cyclic guanosine monophosphate Organic chemistry Chemistry PDE5 inhibitors		EMA/CHMP[removed]EMEA/H/C/202 Add to Reading List Source URL: www.ema.europa.eu Download Document from Source Website File Size: 97,22 KB Share Document on Facebook

	Microsoft Word - abstracts_compiled.doc DocID: 1rn3E - View Document
	Research Review No. 95. Tadalafil Amelioration of Duchenne Muscular Dystrophy The Studies: The authors of the publication (1) from Rome, Italy, examined the effects of treating mdx mice, i.e. mice having a mutation in DocID: 1p1fj - View Document
	VIAGRA® 25 mg, 50 mg or 100 mg film-coated tablets Sildenafil Package leaflet: Information for the patient Read all of this leaflet carefully before you start taking this medicine because it contains DocID: 1oVQV - View Document
	Special Feature Nippon Shinyaku Launches Zalutia®, a Breakthrough New Drug for Urinary Disorders Caused by Benign Prostatic Hypertrophy Benign prostatic hypertrophy, or BPH, negatively affects a patient’s quality of DocID: 1aqHy - View Document
	VIAGRA® (sildenafil citrate) Tablets DESCRIPTION VIAGRA®, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodies DocID: 196xE - View Document